Meeting
2022 ASCO Genitourinary Cancers Symposium
US physician perceptions of treatment decision making for advanced renal cell carcinoma.
Authors
Daniel M. Geynisman
Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA
Daniel M. Geynisman , Jonathan Kish , Angelica Falkenstein , Viviana Del Tejo , Stephen Huo , Alexandrina Balanean , Bruce A. Feinberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 311)
DOI
10.1200/JCO.2022.40.6_suppl.311
Abstract #
311
Poster Bd #
E1
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Network meta-analysis (NMA) of first-line advanced renal cell carcinoma (1L aRCC) treatments: Development of a decision algorithm for fractional polynomial (FP) model selection.
First Author: Bradley Alexander McGregor
Poster
2024 ASCO Genitourinary Cancers Symposium
Pembrolizumab plus lenvatinib (P+L) versus alternative therapies in first-line (1L) advanced renal cell carcinoma (aRCC) by IMDC risk status: A network meta-analysis (NMA).
First Author: Pratik Rane
Poster
2024 ASCO Genitourinary Cancers Symposium
Pembrolizumab plus lenvatinib (P+L) versus alternate therapies in first-line (1L) for advanced renal cell carcinoma (aRCC): A network meta-analysis (NMA).
First Author: Kevin Yan
Poster
2024 ASCO Genitourinary Cancers Symposium
Network meta-analysis (NMA) to assess comparative efficacy of lenvatinib plus pembrolizumab compared with other first-line treatments for management of advanced renal cell carcinoma (aRCC).
First Author: Viktor Grünwald